Skip to main content
. 2019 Apr 18;4(8):e123987. doi: 10.1172/jci.insight.123987

Figure 7. Haloperidol inhibits αSMA expression by lung myofibroblasts in vivo.

Figure 7

(A) Schematic of lung fibrosis induced by intratracheal injection of bleomycin (orange). (B) Representative images of lung sections of COLL-EGFP mice exposed to bleomycin and treated with either PBS (control) or haloperidol. Nuclei are stained blue with Hoechst. (C) Quantification of the COLL-EGFP+ area in lungs exposed to bleomycin upon treatment with either PBS or haloperidol (n = 4/gp). (D) Quantification of the mean cell intensity of COLL-EGFP+ in lung fibroblasts exposed to bleomycin upon treatment with either PBS or haloperidol (n = 4/gp). (E) Representative images of lung sections from mice exposed to bleomycin upon treatment with either PBS (control) or haloperidol, stained red with anti-αSMA antibodies. Nuclei are stained blue with Hoechst. (F) Quantification of αSMA+ area in lungs of mice exposed to bleomycin upon treatment with either PBS or haloperidol (n = 4/gp). (G) Quantification of the mean cell intensity of αSMA+ in lung fibroblasts exposed to bleomycin upon treatment with either PBS or haloperidol (n = 4/gp). Scale bars: 1 mm (B) and 50 μm (E). Values in C, D, F, and G are mean ± SEM.*P < 0.05, **P < 0.01 by unpaired t test.